Table 2 Summary of study characteristics and costs per DALY averted for interventions targeting pregnant women
References | Publication year | Country/region | Malaria intervention | Main data sources | Life tables source | Cost-effectiveness threshold used | Cost-effectiveness ratio (cost per DALY averted) | DALYs averted per $ 1 million spent on intervention |
|---|---|---|---|---|---|---|---|---|
[1] | 1999 | Sub-Saharan Africa | ITNs, residual spraying, chemoprophylaxis and improved malaria treatment | Published and unpublished sources Programmes | GBD study | US$ 30–US$ 150 | $4–$10 for treatment of existing nets | 142,857 |
$19–$85 for residual spraying | 19,231 | |||||||
$3–$12 chemoprophylaxis for children | 133,333 | |||||||
$4–$29 for pregnant women treatment | 58,997 | |||||||
$1–$8 for case management | 222,222 | |||||||
[2] | 2001 | Non-specific | Sulfadoxine–pyrimethamine | Published and unpublished data | Kenyan life table | Not stated | $10–14 | 83,333 |
[3] | 2009 | DRC | Insecticide treated nets (ITNs) distribution | Clinic records, program records and peer-reviewed literature | WHO life table | 1–3 times GDP per capita | $17.22 | 58,072 |
[4] | 2010 | Mozambique | Intermittent preventive treatment | Demographic surveillance system | Mozambique life table | US$ 36–US$ 129 | $41.46 (maternal malaria) | 24,120 |
[5] | 2015 | Model | Intermittent preventive treatment | Published data | GBD (2010 and 2004) | 1–3 times GDP per capita | $7.28 | 137,363 |
[6] | 2015 | Multi-country | Intermittent preventive treatment | Clinical trials Published data | Country-specific | US$ 240 | $136.30 | 7337 |